Valuation: Royalty Pharma plc

Market Cap 25.48B 22.12B 20.63B 18.95B 35.84B 2,424B 36.23B 243B 95.07B 1,212B 95.68B 93.59B 4,014B P/E 2026 *
21.7x
P/E 2027 * 17x
Enterprise Value 34.63B 30.07B 28.04B 25.76B 48.71B 3,294B 49.25B 331B 129B 1,647B 130B 127B 5,457B EV / Sales 2026 *
9.98x
EV / Sales 2027 * 9.3x
Free-Float
71.97%
Yield 2026 *
1.74%
Yield 2027 * 1.83%
1 day+0.54%
1 week-4.15%
Current month-1.63%
1 month-0.50%
3 months+14.50%
6 months+31.59%
Current year+48.76%
1 week 56.36
Extreme 56.36
59.67
1 month 54.95
Extreme 54.95
60.44
Current year 38.29
Extreme 38.29
60.44
1 year 34.08
Extreme 34.0805
60.44
3 years 24.05
Extreme 24.05
60.44
5 years 24.05
Extreme 24.05
60.44
10 years 24.05
Extreme 24.05
60.44
Manager TitleAgeSince
Chief Executive Officer 62 1995-12-31
Director of Finance/CFO 44 2009-12-31
Chief Tech/Sci/R&D Officer - 2023-09-20
Director TitleAgeSince
Chairman 62 2020-03-31
Director/Board Member 68 2020-02-10
Director/Board Member 63 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
7/1/26 Sell

Executive/Senior Manager

-9,099 0.0021%
6/30/26 Sell

Executive/Senior Manager

-130,000 0.0293%
6/30/26 Free

Director

689 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+0.54%-4.15%+51.74%+87.84% 25.48B
-0.51%-8.60%+45.08%+148.21% 995B
+0.20%-4.42%+49.05%+50.81% 614B
-0.53%-7.37%+23.64%+65.03% 431B
+0.84%-0.08%+41.50%+36.45% 353B
-0.10%-3.85%+30.66%+38.83% 293B
-1.12%-11.44%+3.66%+6.84% 245B
-4.14%-12.48%-3.29%-45.79% 210B
+2.94%-0.78%+29.17%+60.32% 210B
+3.13%+0.69%+18.11%+71.90% 168B
Average +0.25%-4.93%+28.93%+52.05% 354.37B
Weighted average by Cap. +0.20%-5.88%+33.72%+70.55%

Financials

2026 *2027 *
Net sales 3.47B 3.01B 2.81B 2.58B 4.88B 330B 4.93B 33.12B 12.95B 165B 13.03B 12.74B 547B 3.74B 3.25B 3.03B 2.78B 5.26B 356B 5.32B 35.7B 13.96B 178B 14.05B 13.74B 589B
Net income 1.65B 1.44B 1.34B 1.23B 2.33B 157B 2.35B 15.79B 6.17B 78.64B 6.21B 6.07B 261B 2.06B 1.79B 1.67B 1.53B 2.9B 196B 2.93B 19.66B 7.69B 97.94B 7.73B 7.57B 325B
Net Debt 9.15B 7.95B 7.41B 6.81B 12.87B 871B 13.02B 87.37B 34.15B 435B 34.37B 33.62B 1,442B 9.33B 8.1B 7.55B 6.94B 13.12B 887B 13.26B 89B 34.79B 443B 35.02B 34.25B 1,469B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Employees
100
Date Price Change Volume
26-08-04 US$57.48 +0.54% 3,684,203
26-08-03 US$57.17 -2.16% 2,747,780
26-07-31 US$58.43 -1.00% 2,156,928
26-07-30 US$59.02 -0.27% 2,846,336
26-07-29 US$59.18 -1.32% 2,599,135
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
57.48USD
Average target price
61.62USD
Spread / Average Target
+7.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RPRX Stock